Truist Securities Maintains Buy on Disc Medicine, Raises Price Target to $114

Benzinga · 11/10/2025 16:24
Truist Securities analyst Danielle Brill maintains Disc Medicine (NASDAQ:IRON) with a Buy and raises the price target from $86 to $114.